Overview

A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Status:
Active, not recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Primary objective: To determine the incidence of infusion related reactions (IRR's) in the first 6 months of daratumumab administration.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Myeloma Research Group
Myeloma Canada Research Network
Treatments:
Antibodies, Monoclonal
Daratumumab